An example would be Bevacizumab (Avastin, Genentech) that targets the glycoprotein Vascular Endothelial Growth Factor (VEGF), dysregulation of which leads to angiogenesis in metastatic breast cancer, colorectal cancer and Non-small cell lung cancer (NSCLC) (3). Here, VEGFA is linked to non-small cell lung carcinoma.